ONHS Report: HT942526PCARPTRPA

DoW Pancreatic Cancer Research Program, Translational Research Partnership Award

Solicitation ID: HT942526PCARPTRPA

Agency: DHA

Type: Grant

Deadline: 2026-10-07T00:00:00 ET

Eligibility: Yes (Unrestricted)

Funding: Approximately $6.60M total to fund about six awards, with a combined total cost cap of $1.10M per award.

Doc Type: BAA

Clearance: No

Program Manager: N/A

Last Updated: 2026-08-19 15:03

Analyzed File: HT942526PCARPTRPA_GG.pdf

Eligibility Reasoning

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities... applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged.

Note: This is an AI-generated summary...

Summary

The Fiscal Year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award (HT942526PCARPTRPA) supports synergistic partnerships between two Principal Investigators (an Initiating PI and a Partnering PI) to accelerate promising ideas in pancreatic cancer towards clinical application. The program anticipates funding approximately six awards from a $6.60 million allotment, with a combined total cost cap of $1.10 million per award for a maximum performance period of three years. All proposals must address at least one of the FY26 PCARP Focus Areas, such as early detection, new therapeutic targets, or understanding tumor development. The award requires preliminary data to support feasibility and allows for retrospective analyses, correlative studies, and pilot clinical trials, but not large-scale clinical trials. The application process is two-phased, with a mandatory pre-application due July 7, 2026, and an invited full application due October 7, 2026.

Overall Technical Areas

Pancreatic Cancer ResearchTranslational ScienceEarly Detection ResearchCancer Risk CharacterizationSupportive Care ResearchMetabolic Disruption ResearchTumor Development & MetastasisPredictive Biomarker DevelopmentNovel Therapeutic DevelopmentRetrospective Tissue AnalysisCorrelative Clinical StudiesPilot Clinical Trial DesignStatistical Analysis PlanningPreclinical Animal Modeling

Probable LBNL Areas

N/A

Focus Areas

Example Priorities:

Early detection research.
Identification and characterization of risk.
Supportive care, quality of life and survivorship research.
Understanding metabolic disruptions and their systemic effects, including diabetes and cachexia.
Understanding tumor development from precursors to metastasis.
Biomarkers to predict therapeutic response and guide management strategies.
New therapeutic targets and approaches.

Specific Technical Skills:

Early detection researchRisk characterizationSupportive careQuality of life researchSurvivorship researchTumor metabolismDiabetes and cachexiaTumorigenesisMetastasis researchBiomarker discoveryTherapeutic response predictionDrug discoveryNovel therapeutics

Potential PIs for this Area:

Name	Score	Organization

Potential LBNL PIs (Overall)

Note on PI Matching: These suggestions are generated through an AI-driven semantic analysis of LBNL staff profiles.

Name	Score	Organization
Jian-Hua Mao	0.74	BSA \| Biological Systems & Engineering \| Department of BioEngineering and BioMedical Sciences · Cancer Risk Characterization
James Garbe	0.74	BSA \| Biological Systems & Engineering \| Department of BioEngineering and BioMedical Sciences · Retrospective Tissue Analysis
Jennifer Rosenbluth	0.73	· Early Detection Research
Yang Tian	0.73	BSA \| Env. Genomics & Sys. Biology \| Molecular Ecosystems Bio · Metabolic Disruption Research
Ling Jin	0.72	ETA \| Energy Analysis \| Systems & Energy Tech Analysis · Statistical Analysis Planning
Carolyn Larabell	0.72	BSA \| Molecular Biophysics & Integrated Bioimaging \| Bioenergetics Dept · Metabolic Disruption Research
Zixi Hu	0.71	CSA \| AMCR \| Mathematics · Statistical Analysis Planning
Gerard Marriott	0.71	BSA \| Molecular Biophysics & Integrated Bioimaging \| Cellular & Tissue Image · Novel Therapeutic Development
Aris Polyzos	0.71	BSA \| Molecular Biophysics & Integrated Bioimaging \| Cellular & Tissue Image · Novel Therapeutic Development
Eleanor Zizka	0.71	BSA \| Biological Systems & Engineering \| Department of BioEngineering and BioMedical Sciences · Correlative Clinical Studies

Fundamental Research Exemption (FRE)

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities.